Reproductive Health News

ANAHEIM, Calif. — Weight change between two pregnancies conceived through assisted reproductive technology was not associated with adverse pregnancy outcomes, according to findings presented here.

ANAHEIM, Calif. — Only half of hospitals across the United States offer health care specifically to transgender and gender-diverse people, and only 23% of those offer fertility care to this population.

ANAHEIM, Calif. — Laparoscopically confirmed endometriosis was associated with increased levels of 15 plasma proteins, data presented here showed.

ANAHEIM, Calif. — Embryos had a lower blastocyst yield when exposed to wildfire smoke during development, according to data presented here.

WASHINGTON — Some infants with in utero or early life exposure to SARS-CoV-2 had borderline to low developmental scores, a study found, and this was most common among babies born to mothers with symptomatic COVID-19.

From Oct. 22 to 26, ASRM will host its Scientific Congress & Expo in a fully in-person format for the first time in 3 years.

The FDA Obstetrics, Reproductive and Urologic Drugs Advisory Committee voted 14-1 to remove a drug indicated for preventing preterm birth from the market due to lack of effectiveness.

A telemedicine program at Penn Medicine in Philadelphia halved patients’ time from initial visit for fertility care to receipt of treatment, data published in NEJM Catalyst Innovations in Care Delivery showed.

Potentially perimenopausal women who took relugolix combination therapy for uterine fibroids and heavy menstrual bleeding experienced significant reductions in menstrual bleeding and fibroid-related pain vs. those who took placebo.

The benefits of gender-affirming hormone therapy outweigh the risks for transgender women of all ages as well as those with comorbidities, according to a speaker at the 2022 North American Menopause Society annual meeting.